Interim 1-month analysis of a phase 1 trial in 128 older adults: bivalent RSV–hMPV vaccine VXB-241 raised RSV and hMPV neutralising antibodies vs placebo with no safety signal; solicited adverse events 35.0–59.1% vs 23.8% placebo and 76.2% with RSVPreF3.
RCTn = 128
Della Cioppa et al. Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo- and active-controlled, phase 1 trial